Status:
COMPLETED
Edoxaban Treatment in Routine Clinical Practice for Patients With Non-Valvular Atrial Fibrillation (NVAF)
Lead Sponsor:
Daiichi Sankyo (Thailand) Ltd., a Daiichi Sankyo Company
Conditions:
Atrial Fibrillation
Eligibility:
All Genders
18+ years
Brief Summary
In order to understand the risks and benefits of edoxaban use in a real-world clinical setting in the NVAF indication, Daiichi-Sankyo Thailand proposed this non-interventional study (NIS) to gain insi...
Detailed Description
Edoxaban was recently approved by The Thai Food and Drug Administration (Thai FDA) (date: 2nd December 2016) for the prevention of stroke and systemic embolism in adult patients with NVAF with one or ...
Eligibility Criteria
Inclusion
- Is a NVAF-patient whose physician has made the clinical decision to prescribe edoxaban therapy according to Package Information
- Has provided written informed consent to participate in the study
Exclusion
- Is participating in an interventional study
Key Trial Info
Start Date :
October 18 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 28 2022
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT03247569
Start Date
October 18 2017
End Date
February 28 2022
Last Update
May 6 2022
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Srinagarind Hospital and Queen Sirikit Heart Center of the Northeast
Khon Kaen, Muang District, Thailand, 40002
2
Bangkok Heart Hospital
Bangkok, Thailand
3
Bhumibol Adulyadej Hospital
Bangkok, Thailand
4
Bangkok Hospital Chiang Mai
Chiang Mai, Thailand